A krónikus lymphoid leukaemia mai kezelésének interdiszciplináris kérdései = Interdisciplinary approach to the current management of chronic lymphocytic leukemia

Szász, Róbert and Illés, Árpád (2021) A krónikus lymphoid leukaemia mai kezelésének interdiszciplináris kérdései = Interdisciplinary approach to the current management of chronic lymphocytic leukemia. ORVOSI HETILAP, 162 (9). pp. 336-343. ISSN 0030-6002

Preview

Text article-p336.pdf Available under License Creative Commons Attribution. Download (166kB) | Preview

Abstract

Chronic lymphocytic leukemia (CLL) is ubiquitously treated with novel agents. The Bruton?s tyrosine kinase inhibi-tor ibrutinib and the B-cell lymphoma 2 inhibitor venetoclax can be used increasingly in earlier lines of treatment with improved progression-free survival. Treatment with targeted small molecules fundamentally changed not only the course of CLL but also the care of patients. With the administration of long-term oral medications, patients are more likely to show up at specialist clinics that match their complaints. In addition to the effects and side effects of the new drugs, attention should also be drawn to basic drug interactions. The effect of ibrutinib on blood pressure and the ability to provoke atrial fibrillation in 6?16% of cases are of paramount importance. In addition to drug in-teractions, the treatment of the latter is also complicated by the hemorrhagic effect of ibrutinib. Knowledge on CLL and its treatment is also important in the approach to secondary tumors, some gastrointestinal and dermatological diseases. The potential for tumor lysis syndrome of venetoclax requires close collaboration with nephrologists. In order to provide appropriate professional care and optimize patient pathways, close co-operation between GPs, emer-gency care providers and other specialist care facilities is required within the framework of professional consultation.

Actions (login required)

Edit Item